The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial

Marianne Melau, Pia Jeppesen, Anne Thorup, Mette Bertelsen, Lone Petersen, Christian Gluud, Gertrud Krarup, Merete Nordentoft, Marianne Melau, Pia Jeppesen, Anne Thorup, Mette Bertelsen, Lone Petersen, Christian Gluud, Gertrud Krarup, Merete Nordentoft

Abstract

Background: The Danish OPUS I trial randomized 547 patients with first-episode psychosis to a two-year early-specialised assertive treatment programme (OPUS) versus standard treatment. The two years OPUS treatment had significant positive effects on psychotic and negative symptoms, secondary substance abuse, treatment adherence, lower dosage of antipsychotic medication, and a higher treatment satisfaction. However, three years after end of the OPUS treatment, the positive clinical effects were not sustained, except that OPUS-treated patients were significantly less likely to be institutionalised compared with standard-treated patients. The major objective of the OPUS II trial is to evaluate the effects of five years of OPUS treatment versus two years of OPUS treatment.

Methods: The OPUS II trial is designed as a randomized, open label, parallel group trial with blinded outcome assessment. Based on our sample size estimation, 400 patients treated in OPUS for two years will be randomized to further three years of OPUS treatment versus standard treatment. The specialized assertive OPUS treatment consists of three core elements: assertive community treatment, psycho-educational family treatment, and social skills training.

Discussion: It has been hypothesized that there is a critical period from onset up to five years, which represents a window of opportunity where a long-term course can be influenced. Extending the specialized assertive OPUS treatment up to five years may allow the beneficial effects to continue beyond the high-risk period, through consolidation of improved social and functional outcome.

Trial registration: Clinical Trial.gov NCT00914238.

Figures

Figure 1
Figure 1
CONSORT diagram depicting flow of study participants in the OPUS II trial.

References

    1. World Health Organization. Diagnostic criteria for research. 1. Geneva: World Health Organization; 1993. The ICD-10 Classification of Mental and Behavioural Disorders.
    1. Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. Suicide Life Threat Behav. 2000;30(1):34–49.
    1. Nordentoft M, Laursen TM, Agerbo E, Qin P, Hoyer EH, Mortensen PB. Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study. British Medical Journal. 2004;329:261–266. doi: 10.1136/bmj.38133.622488.63.
    1. Angemeyer MC. Schizophrenia and violence. Acta Psychiatr Scand suppl. 2000. pp. 63–67.
    1. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279–293.
    1. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53–59.
    1. Cahn W, Van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA. et al.Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 2006;189:381–382. doi: 10.1192/bjp.bp.105.015701.
    1. Jeppesen P, Petersen L, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO. et al.The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychological Medicine. 2008;38(8):1157–1166. doi: 10.1017/S0033291708003449.
    1. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and in cohorts of first-episode outcome patients - A systematic review. Arch Gen Psychiatry. 2005;62(9):975–983. doi: 10.1001/archpsyc.62.9.975.
    1. National Institute for Clinical Excellence. Schizophrenia. Full national clinical guideline for interventions in primary and secondary care. London: Royal College of Psychiatrist and British Psychological Society; 2006.
    1. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal. 1998;317(7167):1181–1184.
    1. Petersen L, Jeppesen P, Thorup A, Abel MJ, Ohlenschlaeger J, Christensen TO. et al.A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal. 2005;331(7517):602–605. doi: 10.1136/bmj.38565.415000.E01.
    1. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, Le Quach P. et al.Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness. Arch Gen Psychiatry. 2008;65(7):762–771. doi: 10.1001/archpsyc.65.7.762.
    1. Craig TKJ, The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised for early psychosis. BMJ. 2004.
    1. Referenceprogram for skizofreni. Copenhagen, DK: The Danish National Board of Health; 2004. Centre for Evaluating and Medical technolog assessesment.
    1. Mcgrew JH, Bond GR, Dietzen L, Salyers M. Measuring the Fidelity of Implementation of A Mental-Health Program Model. Journal of Consulting and Clinical Psychology. 1994;62(4):670–678. doi: 10.1037/0022-006X.62.4.670.
    1. Andreasen NC. Scale of the Assesment of Negative Symptoms/Scale for the Assessement of Positive Symptoms (Manual) Iowa City, University of Iowa Press; 1884. Ref Type: Generic.
    1. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46(4):354–357.
    1. Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82–84.
    1. Danmarks Statistik (The Danish National Bureau of Statistics) IDA en integreret database for arbejdsmarkedsforskning (IDA an integrated database of labormarket research) Copenhagen, Denmark's Statistics Press; 1991. Ref Type: Report.
    1. laegemiddelstyrrelsen. medicinal product database at the website of Statistics Denmark. Lægemiddelstyrelsen. 2011.
    1. Pocock SJ. Clinical Trials. A Practical Approach. Chichester New York Brisbane Toronto Singapore: John Wiley & Sons; 1996.
    1. Keus F. WJGCvLCJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol. 2010;1(10):90. doi: 10.1186/1471-2288-10-90.
    1. Thorup A, Petersen L, Jeppesen P, Nordentoft M. The quality of life among first-episode psychotic patients in the opus trial. Schizophrenia Research. 2010;116(1):27–34. doi: 10.1016/j.schres.2009.10.006.
    1. Albert N, Bertelsen M, Thorup A, Petersen L, Jeppesen P, Krarup G. et al.Analyses of Protective Factors for Patients with A Good Outcome Five Year After First Episode Psychosis. Schizophrenia Research. 2010;117(2-3):179. doi: 10.1016/j.schres.2010.02.217.
    1. McGlashan TH, Fenton WS. The Positive-Negative Distinction in Schizophrenia - Review of Natural-History Validators. Arch Gen Psychiatry. 1992;49(1):63–72.
    1. Ho BC, Psych MRC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. American Journal of Psychiatry. 1998;155(9):1196–1201.
    1. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R. et al.SCAN: Schedule for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47:589–593.
    1. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry. 1995;52(5):352–360.
    1. Hamilton MA. Rating scale for depression. J Neurol Neurosurg Psychiat. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Klingberg S. IRAOS - Interview for retrospective determination of disease onset and course in schizophrenia and other psychoses. Zeitschrift fur Klinische Psychologie und Psychotherapie. 2002;31(1):65–66. doi: 10.1026//1616-3443.31.1.65.
    1. Tegeler D, Juckel G. Validation of Personal and Social Performance Scale (PSP) on random test of acute schizophrenic patients. Nervenarzt. 2007;78(74)
    1. Endicott J, Spitzer RL, Fleiss JL, Cohen J. Global Assessment Scale - Procedure for Measuring Overall Severity of Psychiatric Disturbance. Arch Gen Psychiatry. 1976;33(6):766–771.
    1. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC. et al.A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5–19. doi: 10.1093/schbul/sbi020.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The Uku Side-Effect Rating-Scale - A New Comprehensive Rating-Scale for Psychotropic-Drugs and A Cross-Sectional Study of Side-Effects in Neuroleptic-Treated Patients - Preface. Acta Psychiatrica Scandinavica. 1987;76:7. doi: 10.1111/j.1600-0447.1987.tb10566.x.
    1. Luszczynska A, Scholz U, Schwarzer R. The general self-efficacy scale: Multicultural validation studies. Journal of Psychology. 2005;139(5):439–457. doi: 10.3200/JRLP.139.5.439-457.
    1. Horvath AO, Greenberg LS. Development and Validation of the Working Alliance Inventory. Journal of Counseling Psychology. 1989;36(2):223–233. doi: 10.1037/0022-0167.36.2.223.
    1. Norholm V, Bech P. The WHO Quality of Life (WHOQOL) Questionnaire: Danish validation study. Nordic Journal of Psychiatry. 2001;55(4):229–235. doi: 10.1080/080394801681019075.
    1. Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5(3):233–237. doi: 10.1016/0149-7189(82)90074-X.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit